IMUX Valuation
Immunic Inc
$
1.150
- Overview
- Forecast
- Valuation
IMUX Relative Valuation
IMUX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IMUX is overvalued; if below, it's undervalued.
Historical Valuation
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
5.63
P/B
Median3y
1.54
Median5y
1.82
-75.85
FCF Yield
Median3y
-81.85
Median5y
-57.19
Competitors Valuation Multiple
The average P/S ratio for IMUX's competitors is 0.28, providing a benchmark for relative valuation. Immunic Inc Corp (IMUX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
EHAB
Enhabit Inc
8.050
USD
+2.55%
GNTY
Guaranty Bancshares Inc
39.770
USD
+1.35%
OTLY
Oatly Group AB (publ)
10.740
USD
-4.36%
HYLN
Hyliion Holdings Corp
1.620
USD
+7.28%
NIPG
NIP Group Inc
1.720
USD
+3.61%
NVEC
NVE Corp
62.200
USD
+3.19%
NOVA
Sunnova Energy International Inc
0.180
USD
-8.16%
MTRX
Matrix Service Co
12.490
USD
+2.97%
PKST
Peakstone Realty Trust
11.510
USD
+0.96%
BKKT
Bakkt Holdings Inc
9.980
USD
-4.41%
FAQ
Is Immunic Inc (IMUX) currently overvalued or undervalued?
Immunic Inc (IMUX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 1201.95. The fair price of Immunic Inc (IMUX) is between to according to relative valuation methord.
What is Immunic Inc (IMUX) fair value?
How does IMUX's valuation metrics compare to the industry average?
What is the current P/B ratio for Immunic Inc (IMUX) as of May 04 2025?
What is the current FCF Yield for Immunic Inc (IMUX) as of May 04 2025?
What is the current Forward P/E ratio for Immunic Inc (IMUX) as of May 04 2025?